These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 9918216)

  • 1. Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3.
    Strauss G; Gückel B; Wallwiener D; Moldenhauer G
    Clin Cancer Res; 1999 Jan; 5(1):171-80. PubMed ID: 9918216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
    Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
    Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
    Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
    Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian malignant ascites-derived lymphocytes stimulated with prothymosin α or its immunoactive decapeptide lyse autologous tumour cells in vitro and retard tumour growth in SCID mice.
    Voutsas IF; Pistamaltzian N; Tsiatas ML; Skopeliti M; Katsila T; Mavrothalassiti I; Spyrou S; Dimopoulos MA; Tsitsilonis OE; Bamias A
    Eur J Cancer; 2013 May; 49(7):1706-14. PubMed ID: 23276721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphocytes infiltrating ovarian malignant ascites: modulation of IL-2-induced proliferation by IL-4 and of selective increase in CD8+ T cells by TNF-alpha.
    Ioannides CG; Rashed S; Fisk B; Fan D; Itoh K; Freedman RS
    Lymphokine Cytokine Res; 1991 Aug; 10(4):307-15. PubMed ID: 1932375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites.
    Ioannides CG; Platsoucas CD; Rashed S; Wharton JT; Edwards CL; Freedman RS
    Cancer Res; 1991 Aug; 51(16):4257-65. PubMed ID: 1868446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
    Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
    Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
    Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphokine-activated killer activity of tumor-associated and peripheral blood lymphocytes isolated from patients with ascites ovarian tumors.
    Allavena P; Zanaboni F; Rossini S; Merendino A; Bonazzi C; Vassena L; Mangioni C; Mantovani A
    J Natl Cancer Inst; 1986 Oct; 77(4):863-8. PubMed ID: 3489856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
    Woo EY; Chu CS; Goletz TJ; Schlienger K; Yeh H; Coukos G; Rubin SC; Kaiser LR; June CH
    Cancer Res; 2001 Jun; 61(12):4766-72. PubMed ID: 11406550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
    Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
    Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The comparison of biological characteristics between tumor-infiltrating lymphocytes and tumor-associated lymphocytes in ascites of epithelial ovarian carcinoma].
    Kang S; Shen K; Lang J
    Zhonghua Fu Chan Ke Za Zhi; 1998 Oct; 33(10):607-10. PubMed ID: 10806687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel system for generating cytotoxic effector lymphocytes using carcinoembryonic antigen (CEA) peptide and cultured dendritic cells.
    Ohta K; Yamaguchi Y; Shimizu K; Miyahara E; Toge T
    Anticancer Res; 2002; 22(5):2597-606. PubMed ID: 12529970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
    Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
    Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infiltration of interleukin-2-inducible killer cells in ascitic fluid and pleural effusions of advanced cancer patients.
    Blanchard DK; Kavanagh JJ; Sinkovics JG; Cavanagh D; Hewitt SM; Djeu JY
    Cancer Res; 1988 Nov; 48(22):6321-7. PubMed ID: 2972357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma.
    Lai P; Rabinowich H; Crowley-Nowick PA; Bell MC; Mantovani G; Whiteside TL
    Clin Cancer Res; 1996 Jan; 2(1):161-73. PubMed ID: 9816103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical application of adoptive immunotherapy by cytotoxic T lymphocytes induced from tumor-infiltrating lymphocytes].
    Yamaue H; Tanimura H; Tsunoda T; Iwahashi M; Tani M; Inoue M; Tamai M
    Nihon Gan Chiryo Gakkai Shi; 1990 May; 25(5):978-89. PubMed ID: 2391445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model.
    Ren-Heidenreich L; Davol PA; Kouttab NM; Elfenbein GJ; Lum LG
    Cancer; 2004 Mar; 100(5):1095-103. PubMed ID: 14983507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab.
    Kornacker M; Verneris M; Kornacker B; Ganten T; Scheffold C; Negrin R
    Cytotherapy; 2006; 8(1):13-23. PubMed ID: 16627341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.